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Four opioid pcptides were isolated rrom the enzymatic digest of wheat gluten. Their struclurcs were Gly-Tyr-Tyr-Pro-Thr, Gly-Tyr-Tyr-Pro,Tyr- 
GlyGly-Trp-Leu and Tyr-Gly-Gly-Trp. which were named gluten cxorphins AS, A4. I35 and B4, respectively. The gluten cxorphin AS sequence 
was found al I5 sites in Ihe primary structure or the high molecular weight glutenin and was highly specific for ckcep~ors. The struaurc-aaivhy 
relationships orglulcn cxorphins A were unique in lhal the presence bfGly al their N-termini increased their aclivitics. Gluten cxorphin B5. which 
corresponds to [TrpJ.Leus]cnkephalin, showed the mosi polcnl activity among thcsc peptides. Its IC,, values wcrc 0.05 ,uM and 0.017 PM. 
respectively. on Ihe GPI and the MVD assays. 
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1. INTRODIJCTION 
The presence of opioid peptides in the enzymatic 
digests of wheat gluten have been recognized. Zioudrou 
et al. found the opioid activity in the peptic digest of 
wheat gluten in the assays of both the inhibition of the 
contraction of the electrically stimulated mouse vas de- 
ferens and the inhibition of adenylate cyclase of neuro- 
blastoma X-glioma hybrid cells [ 11. Huebner et al. also 
recognized the presence by the radioreceptor assay [2]. 
On the other hand, the oral administration of wheat 
gluten digests prolonged the intestine transit time or 
increased the plasma insulin level, and the effects were 
reversed by naloxone [3-Q However, as for the opioid 
peptides derived from wheat gluten, no information 
about their structure and character has been obtained 
until now. In this paper, we reptirt the isolation and the 
characterization of four opioid peptides from the en- 
zymatic digest of wheat gluten. 
2. MATERIALS AND METHODS 
2. I. Chemicrtls und reagents 
Wheat ylutcn was obtained from Goodman Fielder Mills Ltd. 
Pepsin, trypsin and chymotrypsin wcrc from Sigma Chemical Co. 
Aihr~r~iutiotts: GM, guinea pig ileum; MVD, mouse vas deferens; 
DAGO. [D-Ala~.McPhe’.Glycol’]cnkephalin; DADLE, [D-Ala’, Dm 
L&]enkephalin; EKC, cthylkelocyclazocine; ODS, octadecyl silica; 
HPLC, high-performance liquid chromalography; TFA, lrilluoro- 
acclic acid 
Corres/~onc/encc uddrcss: M. Yoshikawa, DepPrlrnent of Food kicncc 
and Technology. Faculty of Agriculture. Kyolo University, Kyoto 
606, Japan. Fax: (81) (75) 753 6274. 
Thermolysin was from Pcplidc Institute Inc. Olhcrcrzymcs used were 
commercial grade. Naloxone WPS rrom U.S.P.C., Inc. [‘HIDAGO, 
[‘HJDADLE and [“H]EKC were from Amcrsham. Other reagents used 
were reagent grade or belter. 
2.2. Enzymuric digesriota of w/trot gltrrett 
Wheat gluten (50 mdml solution) was d&s&xl with pepsin (0.5 
mdml) in 0.02 N HCI (pH 2.0) for I7 h at 36°C. After the d&lion, 
the ~1-1 of the solution was adjusted with I N NaOH lo 7.0. Then, the 
solution was boiled and centrifuged. The supcrnatant was lyophilizcd. 
The peptic digest (50 mdml solution) was further digest& with trypsin 
or eirymotrypsin or thermolysin or other enzymes 10.5 mg/ml, respcc 
tivcly) in distilled water for 5 h al 36*C, boiled and ccntrifug&. 
2.3. PtrrtJkutiort of ycpprirks 
Separrrtions of peptides in the diyesls wcrc accomplished by re- 
versed-phase HPLC on an ODS column (Cosmosil 5C,,-AR. 20 x 250 
mm, Nacalai Tesquc Inc.). A IO0 mg digest was applied to the column 
and was elulcd with a linear gradient between 0 to 40% acctonitrile 
conmining 0.05% TFA at 10 ml/min. The cluatc was monilored at 230 
nm. individual fractions were dried with a centrifugal concentrator 
nnd lheir opioid acliviiies were measured on Lhe MYD assay. The 
opioid active fractions were purified on an ODS column (Cosmosil 
SCIfi-AR, 4.6 x 150 mm), a phcnyl siliw column (Cosmosil 5Ph. 4.6 
x 250 mm) and cynnopropyl silica column (Cosmosil TCN-R, 4.6 x 250 
mm) from Nacalai Tesquc Inc. and a phcnctyl silicacolumn(Dcvelosil 
PhA-5,4.6 x 250 mm) f’rom Nomurd Chemical Inc.. The columns were 
developed by a linear gmdicnl between 0 10 50% acctonilrile contaip 
ing 0.05% TFA or IO mM potassium-sodium phosphate buffer (pH 
7) at I mllmin. The elualc was monitored al 215 nm to 235 nm. The 
active fractions were purified on the same ODS column as the firs1 
step. 
2.4. Opiuid acriviry assays 
The measurements of opioid acdvilies were accomplished by thr 
MVD and GPI assays. As for the MVD assay. mouse vaadcfcrcns was 
suspended with 0.2 g tension in a magnus tubecontainin~ a ME**-free 
Krcbs-Ringer solution und slimulalcd (30 Y. I .2 ms, 0.1 He). As ior 
Ihc GPI assay, the guinea pig ileum was suspended wilh 0.5 g lcnsion 
in a Krcbs-Ringer solution and stimulated (30 V. 0.5 ms. 0.1 Hz). 
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Contraction ws recorded through B isometric trnnsduccr. Thcsc as- 
says wcrc accomplished in the prcscncc or L-lcucyl-L-loucine (2 mM). 
together with bcstatin (30bM), thiorphun (0.3pM). and captopril (IO 
PM). The I& v;~luc is the concentration which inhibits thcelcctrically 
stimulated muscle contrxlion by 50%. 
The presence ol’opioid activities in the enzymutic digcsls ol’wheat 
gluten were judged by the MVD assi+y in the ubscnce and prcscncc 01’ 
IO-& M naloxone. The uctivilics which wwe rcvcned by addition 01 
naloxonc and blocked by pretreatmcnt with niilOXOnc wrrc regarded 
as opioid activities. 
The radioreccptor ussuys wcrc pcrformcd according to the method 
of Pert and Snyder [6] in the prescncc 01’ I nM I’H]DAGO (47.8 
CXmmol) for they-rcccptors or I nM rH]DADLE (30.0 Ci/mmol) TOI 
the &rcceptors nnd rat brain membrane. The radioreccptor assay I’or 
x-receptor was pcrlbrmed in the presence or I nhl pH]EKC (24,5 
Ci/mmol) and guinea pig ccrcbcllum mcmbranc. All iassays were per- 
formed in the presence or inhibitors us well as Ibr opioid activity 
t~ssuys. The IC,,, v;tlue is the concentration which inhibits the binding 
ol’ the labeled ligund by 50%. 
The amino acid scqucnce or the purified pcptidc was t\nalyzed by 
ii 477A protein sequencer (Applied Biosystems Inc.). The pcptidc WBS 
synthesized by H Sam 2 pcptidc synthesizer (Bioscxch Inc.). The 
pcptidc was deprotccted by ths anisollhydrogen fluoride method and 
purified by rcvcrsed-phase HPLC on a ODS column. 
3. RESULTS AND DISCUSSION 
Opioid activities in the enzymatic digests of wheat 
gluten were measured by the MVD assay (Fig. I). All 
these digests inhibited the contraction of the electrically 
stimulated mouse vas deferens. However, these inhibit- 
ing activities were composed of the opioid activities 
which were reversed by naloxone and the non-opioid 
activities which were not reversed by naloxone. Among 
them, the pepsin-thermolysin digen showed the highest 
opioid activity. Thus, to purify the opioid peptides, we 
fractionated the pepsin-thermolysin digest by reversed- 
phase HPLC on an ODS column and assayed the opioid 
activities of individual fractions on the MVD assay 
(Fig. 2). Opioid activities were recovered in four frac- 
tions (fractions 1, 11, 111 and IV) which were eluted at 
23%. 25%. 29% and 34% acetonitrile. respectively (Fig. 
2). The non-opioid activity, which was not reversed by 
naloxone. also was elutcd at 13% acetonitrile. This non- 
opioid substance was identified as adenosine from UV, 
NMR and mass spectra analyses (Data not shown). 
Authentic adenosine also inhibited the contraction of 
the electrically stimulated mouse vas defercns and the 
effect was reversed by its antagonist, theophylline (Data 
not shown). 
We further purified four opioid peptidcs from the 
ODS column by reversed-phase HPLC on different 
columns and obtained four pure peptide fractions, 
which are illustrated by fruction I-3, 11-2. III-3 and IV-5 
(Table 1). The yields of individual pure peptides against 
wheat gluten were 4 x IO-“% (fraction I-3). 4 x IO-‘% 
(fraction 11-Z). 3 x IO-‘% (fraction 111-3). and 1 x lo-‘% 
(fraction IV-5). respectively. The structures of these 
peptides were analyzed with a protein sequencer and the 
sequences obtained were Gly-Tyr-Tyr-Pro-Thr (frac- 
tion l-3), Gly-Tyr-Tyr-Pro (fraction II-Z), Tyr-Gly-Gly- 
Trp (fraction 111-3). and Tyr-Gly-Gly-Trp-Leu (fraction 
IV-5), which were named gluten exorphins A5, A4. B4 
and B5, respectively. Gluten exorphin A5 was an inter- 
spersed repcatcd sequence which was found 15 times in 
the primary structure of the high molecular weight glu- 
tenin [7] (Fig. 3). In addition, Arg-Tyr-Tyr-Pro. Scr- 






Fig. I. ETTecls ol’ enzymatic digests of wheat gluten on the contraction of electrically slimultad mouse vas dekrcns. Naloxonc was added after 
(above) or before (below) tbc addition or the digests. D. IO mg/ml 01’ the enzymatic digest: N. IO-” M naloxone. 
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Fig. 2. Rcvcrscd-phase HPLC 01’ the pepsin- ~hcrmolysin digest on an ODS column. 
Tyr-Tyr-Pro. Trp-Tyr-Tyr-Pro, Gly-Tyr-Tyr-Leu and 
Gly-Tyr-Tyr-Ser, which were hon~ologous to gluten cx- 
orphin A4, were also found in this primary structure. 
On the other hand, gluten exorphins B were not found 
in the primary structure reported of gliadin or glutcnin 
[7-l I]. Wheat gluten is a complex mixture of many 
different proteins. It is possible that gluten exorphins B 
are derived from a wheat protein of which the primary 
structure has not yet been determined. Interestingly, the 
structure of gluLen exorphin BS corresponds LO [Trp”, 
Leu’]enkephalin. This peptide has been synthesized in 
the uudy of the structure-activity relationships of enke- 
phalin derivatives by Schiller et al. [l2]. 
We synthesized these gluten exorphins including their 
analogues and evaluated their opioid activities by the 
MVD and the GPI assays and their receptor affmities 
by the radioreceptor assays (Table II). Gluten ex- 
orphins A displayed opioid activities on the MVD assay 
but not on the GPI assay. Together with the results of 
radioreceptor assays, it is suggested that gluten ex- 
orphins A5 and A4 are &selective ligands. These two 
peptides had no affinity for K-receptors. The activities 
of Tyr-Tyr-Pro-Thr and Tyr-Tyr-Pro, which lack an 
N-terminal Gly of gluten exorphin A5 and A4, were 
very weak. In the case of the analogues, Arg-Tyr-Tyr- 
Pro, Ser-Tyr-Tyr-Pro and Trp-Tyr-Tyr-Pro, in which 
the N-terminal Gly of gluten exorphin A4 is replaced by 
Arg, Scr or Trp, their activities were less potent than 
that of gluten exorphin A4. Especially, Trp-Tyr-Tyr- 
Pro displayed opioid antagonist activity on the MVD 
assay and its, pA2 value was 3.3. In that an N-terminal 
Gly increases the activity, Ihe structure-activity rela- 
tionships of gluten exorphins A are quite different from 
that of the endogenous opioid peptides. In addition, the 
structures of gluten exorphins A are also unique in that 
the two Tyr are continuous. Among the gluten cx- 
orphins A and B, the most potent opioid peptide was 
giutsn e,xurpi& BS. lis :C5” values WX~ 0.05 +:M and 
0.017 ,uM, respectively, on the GPI and the MVD as- 
says. The activity of gluten exorphig R4 was less potent 
than that of gluten exorphin B5. Especially, this was 
remarkable on the MVD assay. It is suggested that Leu5 
is importanl for the potency of &receptors. In this 
resprcl, gluten exorphin I35 is similar to 
[Leulenkephalin. Glulcn cxorphin BS is the most potent 
among all the exogenous opioid pcptidcs cvcr reported. 
The affinity of gluten exorphin B5 for k-receptors, how- 
ever, was remarkably less than those for ,u- and &re- 
ceptors (the I& value was 30 PM). 
Gluten exorphins A and I3 oblained from the pepsin- 
thermolysin digest were not found in other digests of 
wheat gluten with gastro-intestinal protcases as shown 
in Fig. 1. However, they were found in digests which 
wcrc prepared by further hydrolysis of the peptic digest 
with other microbial neutral proleases derived from 
Aspcrgillus oryxe, Bacillus sthilis, ck. (Data nol 
Table I 
Purifictition ol’opioid pcptidcs derived liom the pepsin-lhermolysin 
digest. This lablc shows the number of opioid active liaclions which 
wcrc oblaincd from fractions 1. II, III and IV as tihorvn in Fig. 2 nnd 
lhc acctonikrilc conccntralions in which they wcrc clukd in various 
reversal-phase HPLC 
Number or opioid wivc fractions (% acclonilrilc) 
Column 
Opioid Phcnyl Cyiino- ODS” ODS’ Phen- 
active Traclion PWYl clhyl? 
I I-l l-2 i-3 
(24.5) (19) (18) 
II 11-l II-2 
(33.5) (29) 
III III-I Ill-2 Ill-3 
(30) (76) (31) 
IV IV-I IV-2 IV-3 IV-4 IV-5 
(36.5) (32.5) (18) (31) (29) 
I In the presence of 0.05X TFA 
?In the prcscncc of IO mM poktssium-sodium phosphate bufkr Ipli 
3 
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Fig. 3. The primary swucture 01’ high molecular weight glulenin rcporled by Sugiyama Ed al, [7]. Gluten exorphin A514 is boxed. Homologous 
sequences or gluten exorphin A4 arc underlined. 
shown). In addition, these peptides were resistant to bacterial proteases. A similar example has been 
trypsin and chymotrypsin (Data not shown). These reported concerning the release of,&casomorphin from 
results suggest hat, in vivo, the release of gluten ex- casein, in vivo, where actions of both gastro-intestinal 
orphins A and B from wheat gluten might be accom- and microbial proteases are involved [13]. 
plished by the concerted actions of pepsin and entero- It has been reported that the peptic digest of wheat 
Pcptidcs 
Table II 
Opioid activities and rcccplor alfinitics ol’glutcn exorphins A5, A4, B5 and 134 and their anulogucs 
Receplor affinities (ICY,,) Opioid activities (IC,) 
cH)DACO (“l-i)DADLE GPI MVD 
iu CuMI S QiM) NJ .JJ CuM) 6 0.w 
Gly-Tyr-Tyr-Pro-Thr-Ser 
Gly-Tyr-Tyr-Pro-Thr 
gluten uxorphin A5 
Gly-Tyr-Tyr-Pro 















































gluten exorphin DS 
Tyr-Gly-Gly-Trp 
t;iuUrr ~xWpilii1 B-t 
Tyr-Cily-Gly-Phc-Leu 
[Lculenkcphalin 
0.045 0.005 9 0.05 0.017 2.9 
0.17 0.13 0.94 I.5 3.4 0.44 
0.037 0.003 12.3 0,04 0.004 IO 
(a). not detcrmincd; (b), this pcptidc displayed opioid antagonist activity on the MVD assay. (pA2 value = 3.3) 
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gluten influenced the regulation of gastro-intestinal mo- [a] Schusdeiarra, V., Schick, R., Hollmd. A., DC la Fucmc, A.. 
tility and hormone release, especially insulin, and that Sp&t, J., Maicr, V., Brantl, V. and Pfciffer, E.F. (1983) Peptides 
these effects were inhibited by naloxone [3-S]. It is pos- 4, 205-210. 
sible that gluten exorphins A5, A4, B5 and B4, which 
[5] Mot-Icy. J.E., Levine. AS.. Yamads, T., Gcbhard. R.L.. Prigge. 
W.F., Sllafer, R.B., GOC~Z, F.C. and Silvis, S.E. (1983) Gastrorn- 
were found in this study, might be related to such a 
regulation of physiological functions. t61 
irrology 84. 1517-1523. 
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